Details

Autor(en) / Beteiligte

• Murillo Perez, Carla F.
• Hirschfield, Gideon M.
• Corpechot, Christophe
• Floreani, Annarosa
• Mayo, Marlyn J.
• Meer, Adriaan
• Ponsioen, Cyriel Y.
• Lammers, Willem J.
• Parés, Albert
• Invernizzi, Pietro
• Carbone, Marco
• Maria Battezzati, Pier
• Nevens, Frederik
• Kowdley, Kris V.
• Thorburn, Douglas
• Mason, Andrew L.
• Trivedi, Palak J.
• Lindor, Keith D.
• Bruns, Tony
• Dalekos, George N.
• Gatselis, Nikolaos K.
• Verhelst, Xavier
• Janssen, Harry L.A.
• Hansen, Bettina E.
• Gulamhusein, Aliya

Titel

Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response

Ist Teil von

• Alimentary pharmacology & therapeutics, 2019-11, Vol.50 (10), p.1127-1136

Ort / Verlag

England: Wiley Subscription Services, Inc

Erscheinungsjahr

2019

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Summary Background Fibrosis stage predicts prognosis in patients with chronic liver disease independent of aetiology, although its precise role in risk stratification in patients with primary biliary cholangitis (PBC) remains undefined. Aim To assess the utility of baseline fibrosis stage in predicting long‐term outcomes in the context of biochemical risk stratification Methods In a large and globally representative cohort of patients with PBC, liver biopsies performed from 1980 to 2014 were evaluated. The predictive ability of histologic fibrosis stage in addition to treatment response at 1 year (Toronto/Paris‐II criteria), as well as non‐invasive markers of fibrosis (AST/ALT ratio [AAR], AST to platelet ratio index [APRI], FIB‐4), for transplant‐free survival was assessed with Cox proportional‐hazards models. Results There were 1828 patients with baseline liver biopsy. Advanced histologic fibrosis (stage 3/4) was an independent predictor of survival in addition to non‐invasive measures of fibrosis with the hazard ratios ranging from 1.59 to 2.73 (P < .001). Patients with advanced histologic fibrosis stage had worse survival despite biochemical treatment response, with a 10‐year survival of 76.0%‐86.6% compared to 94.5%‐95.1% depending on the treatment response criteria used. Poor correlations were observed between non‐invasive measures of fibrosis and histologic fibrosis stage. Conclusion Assessment of fibrosis stage grants prognostic value beyond biochemical treatment response at 1 year. This highlights the need to incorporate fibrosis stage in individual risk stratification in patients with PBC, partly to identify those that may derive benefit from novel therapies.